Skip to content

<img width="302" height="74" src="https://therivabio.com/wp-content/uploads/2023/08/TherivaTM-logo-final-White.svg" class="custom-logo" alt="Theriva™ Biologics" decoding="async" />

ABOUT US
OUR SCIENCE
OUR PIPELINE
RESOURCES
CAREERS
INVESTORS
CONTACT

ABOUT US
OUR SCIENCE
OUR PIPELINE
RESOURCES
CAREERS
INVESTORS
CONTACT

<img width="302" height="74" src="https://therivabio.com/wp-content/uploads/2023/08/TherivaTM-logo-final-White.svg" class="custom-logo" alt="Theriva™ Biologics" decoding="async" />

ABOUT US
OUR SCIENCE
OUR PIPELINE
RESOURCES
CAREERS
INVESTORS
CONTACT

Oncolytic adenovirus with hyaluronidase activity that evades neutralizing antibodies: VCN-11

By lsc-webmaster / April 10, 2021

Post navigation

← Previous Resource

Next Resource →

Search

Recent Posts

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Recent Comments

No comments to show.

Archives

April 2023

Categories

Uncategorized

9605 Medical Center Dr.
Suite 270
Rockville, MD 20850
info@therivabio.com

Theriva™

About Us
Our Science
Our Pipeline
Resources
Careers
Contact

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Privacy Policy
Disclaimer

© 2024 Theriva™ Biologics. All rights reserved.